Plasma homocysteine is weakly correlated with plasma endothelin and von willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women

Clinical Chemistry

Volumn 45, Issue 8 I, 1999, Pages 1200-1205

  De Valk De Roo, Gerdien W ^a   Stehouwer, Coen D A ^b   Lambert, Jan ^b   Schalkwijk, Casper G ^c   Van Der Mooren, Marius J ^b   Kluft, Cornelis ^d   Netelenbos, Coen ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIUM DERIVED RELAXING FACTOR; HOMOCYSTEINE; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD VESSEL FUNCTION; CARDIOVASCULAR RISK; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERHOMOCYSTEINEMIA; NORMAL HUMAN; PATIENT SELECTION; POSTMENOPAUSE; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; BRACHIAL ARTERY; ENDOTHELINS; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; HYSTERECTOMY; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; VASODILATION; VON WILLEBRAND FACTOR;

EID: 0032831050     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. Trie European Concerted Action Project. JAMA 1997;277:1775-81.
2. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-62.
3. Boushey CJ, Beresford SAA, Omenn GS, Motulski AG. A quantitative assessment of plasma homocysteine as a risk factor for cardiovascular disease. Probably benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
4. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998;83:550-3.
5. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274: 1526-33.
6. Blom HJ, Boers GH, van den Elzen JP, van Roessel JJ, Trijbels JM, Tangerman A. Differences between premenopausal women and young men in the transamination pathway of rnethionine catabolism, and the protection against vascular disease. Eur J Clin Investig 1988;18:633-8.
7. Andersson A, Hultberg B, Brattström L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem 1992;30:377-9.
8. Wouters MGAJ, Moorrees MTEC, Van der Mooren MJ, Blom HJ, Boers FGHJ, Schellekens LA, et al. Plasma homocysteine and postmenopausal status. Eur J Clin Investig 1995;25:801-5.
9. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-9.
10. Mijatovic V, Kenemans P, Jakobs C, van Baal WM, Peters-Muller ERA, van der Mooren MJ. A randomized controlled study of the effects of 17β-oestradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998;91:432-6.
11. van der Mooren MJ, Demacker PNM, Blom HJ, De Rijke YB, Rolland R. The effects of sequential three monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women. Fertil Steril 1997;67:67-73.
12. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-21.
13. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-4.
14. Welch GN, Loscalzo J. Homocysteine and atherothrombosis [Review]. N Engl J Med 1998;338:1042-50.
15. Thögersen AM, Jansson J, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998;98:2241-7.
16. Blann AD, Miller JP, McCollum CN. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 1997;132:151-6.
17. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057-63.
18. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
19. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
20. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
21. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-6.
22. Cejka J. Enzyme immunoassay for factor VIII related-antigen. Clin Chem 1982;28:1356-8.
23. Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996;10:171-9.
24. Lambert J, Aarsen M, Donker AJM, Stehouwer CDA. Endothelium-dependent and -independent vasodilatation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:705-11.
25. Stehouwer CDA, Lambert J, Donker AJM, Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997;34:55-68.
26. Yanagisawa M, Kurihawa H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;411-5.
27. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. Arterioscler Thromb 1993;13:1412-7.
28. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
29. Savage CO, Pottinger BE, Gaskin G, Lockwood CM, Pusey CD, Pearson JD. Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1991;85:14-9.
30. de Jong SC, Stehouwer CDA, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost 1997;78:1332-7.
31. van den Berg M, Boers GHJ, Franken DG, Blom HJ, van Kamp GJ, Jakobs C, et al. Hyperhomocysteinemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin investig 1995;25:176-81.
32. Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA. Postischemic vasodilation in human forearm is dependent on endothelium-aerived nitric oxide. Am J Physiol 1996;270: H1435-40.
33. Joannides R, Haefeli WE, Linder L, Ricahrd V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91: 1314-9.
34. Celermajer DS, Sorenson K, Ryalls M, Robinson J, Thomas O, Leonard JV, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 1993;22:854-8.
35. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinov MR, et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Investig 1996;98:24-9.
36. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Investig 1993;91:308-18.
37. Lambert J, van den Berg M, Steyn M, Rauwerda JA, Donker AJM, Stehouwer CDA. Familial hyperhomocysteinaemia and endothelium-dependent vasodilation and arterial distensibility of large arteries. Cardiovasc Res 1999;in press.
38. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia [Editorial]. J Clin Investig 1996;98:5-7.